Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

Abiraterone acetate and enzalutamide both improve outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Optimal sequencing for these agents and whether cross-resistance occurs is unknown. Multicentre review of patients with mCRPC treated with abiraterone acetate and pred...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2013-07, Vol.24 (7), p.1802-1807
Hauptverfasser:	Noonan, K.L., North, S., Bitting, R.L., Armstrong, A.J., Ellard, S.L., Chi, K.N.
Format:	Artikel
Sprache:	eng
Schlagworte:	abiraterone acetate Aged Aged, 80 and over Androstenes Androstenols - therapeutic use Antineoplastic agents Antineoplastic Agents - therapeutic use Benzamides Biological and medical sciences Bone Neoplasms - drug therapy Bone Neoplasms - mortality Bone Neoplasms - secondary castration-resistant Disease-Free Survival Drug Resistance, Neoplasm enzalutamide Gynecology. Andrology. Obstetrics Humans Kallikreins - blood Kaplan-Meier Estimate Male Male genital diseases Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Nephrology. Urinary tract diseases Nitriles Pharmacology. Drug treatments Phenylthiohydantoin - analogs & derivatives Phenylthiohydantoin - pharmacology Phenylthiohydantoin - therapeutic use Prostate-Specific Antigen - blood prostatic neoplasms Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Randomized Controlled Trials as Topic Retrospective Studies Treatment Outcome Tumors Tumors of the urinary system Urinary tract. Prostate gland
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!